The Patient Perspective on Psoriasis Disease Remission
April 2018
in “
Journal of Investigative Dermatology
”
Studysummary This study found that psoriasis patients value medication providing substantial clearance of symptoms at an average of $34,208/year, significantly below the annual cost of biologic treatments. Our plain-language summary of this paper — not a Tressless recommendation.
The study explored the perspectives of 37 psoriasis patients on disease remission and their financial willingness for treatments promising at least 12 months of symptom clearance. Patients were willing to pay an average of $175 monthly out-of-pocket, expecting insurance to cover $2,759 monthly. They valued such medication at approximately $34,208 annually, which is below the average cost of biologic medications ($50,000 per year). The findings indicated that most patients did not expect 100% clearance or two years of symptom improvement to consider their psoriasis in remission, suggesting a discrepancy between patient expectations and the high costs of biologic treatments.
